Alkermes PLC (NAS:ALKS)
$ 29.65 0.15 (0.51%) Market Cap: 4.80 Bil Enterprise Value: 4.25 Bil PE Ratio: 15.21 PB Ratio: 3.71 GF Score: 69/100

Alkermes Plc at Cantor Fitzgerald Global Healthcare Conference Transcript

Oct 03, 2019 / 11:45AM GMT
Release Date Price: $17.51 (+1.13%)
Brandon Richard Folkes
Cantor Fitzgerald & Co., Research Division - Analyst

All right. Good morning, and welcome to the second day of the Cantor Fitzgerald Health Care Conference. First up this morning, we have all Alkermes, and with me for Alkermes, we have Jim Frates, the Chief Financial Officer; and Blair Jackson, Senior Vice President, Corporate Planning.

Questions & Answers

Brandon Richard Folkes
Cantor Fitzgerald & Co., Research Division - Analyst

Jim, maybe just to start off for the benefit of those in the audience, could you just give a background on Alkermes and a little bit about what the company does and where you are in your development and your therapeutic focus?

James M. Frates
Alkermes plc - Senior VP & CFO

Sure. Thank you, Brandon. It's great to be back at the Cantor conference here in New York, and thanks for paying attention for the next half hour or so to Alkermes.

Well, we're, I think, a unique company. We've got long-standing experience in CNS drug development

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot